Biggest News Aggregation in the World
📰 Potential Risk News

Page 7 - Potential Risk News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Potential Risk. Real-time updates on events, politics, business and more.

Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Share this article Share this article INDIANAPOLIS and SAN FRANCISCO and LONDON, Jan. 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as...
Puerto Rico United States City Of United Kingdom Daniel Skovronsky Prnewswire Eli Lilly

New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent

Share this article Share this article INDIANAPOLIS, Jan. 26, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) 2800 mg and etesevimab (LY-CoV016) 2800 mg together significantly reduced COVID-19-related hospitalizations and deaths (collectively, "events") in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial, Eli Lilly and Company (NYSE: LLY) announced. Across 1,035 patients, there were 11 events (2.1 percent) in patients taking therapy an...
United States Puerto Rico Molly Mccully Kevin Hern Daniel Skovronsky Dani Barnhizer

Lilly to begin pragmatic study of neutralizing antibody bamlanivimab (LY-CoV555) for COVID-19 in New Mexico

Share this article Share this article INDIANAPOLIS, Dec. 18, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico. Conducting the study in New Mexico will allow for the collection of data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans...
New Mexico United States Molly Mccully Kevin Hern Daniel Skovronsky Dani Barnhizer

Detailed text transcripts for TV channel - CNN - 20170322:05:54:00

Theres two options. one, theres new intelligence, more specific intelligence, the administration has not been direct about that. the other is that a new administration has come in. and has looked at the previous threat stream and maybe their risk tolerance is lower and said, look, were going to put this ban on in the next three days. >> i mean, the rollout of this, theres certainly a lot of questions as to why the department of homeland security gave airlines 96 hours to comply instead of implem...
Risk Tolerance Department Of Homeland Security Aviation Community Potential Risk Security Rollout

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science